



General AML

EBMT 2018 | MAC *versus* RIC allo-HCT in patients with AML in CR2

 Cynthia Umukoro  Stephanie Hill | Mar 27, 2018

Maria H. Gilleece, from [Leeds Cancer Institute](#), Leeds, UK, presented at the [44th Annual Meeting of the European Society for Blood and Marrow Transplantation \(EBMT\)](#), data from a retrospective study by the [Acute Leukemia Working Party \(ALWP\)](#) of the EBMT, which compared the impact of myeloablative (MAC) *versus* reduced intensity (RIC) conditioning on transplant outcomes in different age groups of a large cohort of acute myeloid leukemia (AML) patients in second complete remission (CR2).

In total, 1,879 AML patients in CR2 who received MAC (n = 1,010, median age at transplant = 42.8 years) or RIC (n = 869, median age at transplant = 57.3 years) between 2007–2016 were identified from the EBMT registry and analyzed in this retrospective study.

Key findings:

- **Outcomes in all patients**
 - 2-year leukemia free survival (LFS): 52% (95% CI, 49.5–54.5)
 - 2-year overall survival (OS): 58.7% (95% CI, 56.2–61.2)
 - 2-year relapse incidence (RI): 28.9% (95% CI, 26.7–31.2)
 - 2-year non relapse mortality: 19% (95% CI, 17.2–21)
 - 2-year graft versus host disease (GvHD) relapse free survival (GRFS): 38.7% (95% CI: 36.2–41.1)
 - 2-year chronic GvHD: 37.2%
- In patients aged ≥ 50 years, compared to MAC, RIC decreased NRM (HR = 0.535, $P = 0.0004$) with worse cGVHD (HR = 1.377, $P = 0.03$) but no impact on RI, LFS, GFRS or OS.
- RIC and MAC had similar outcomes in patients < 50 years

The speaker, Maria Gilleece, concluded by noting that “allo-HCT rescues more than 50% of AML patients achieving CR2 post-relapse”. Additionally, the findings of this retrospective study demonstrate that in AML patients in CR2, “RIC allo-HCT reduces procedural mortality in patients ≥ 50 years without increasing RI and provides equivalent outcomes to MAC allo-HCT in patients < 50 years”. She further added that the findings of this study should be confirmed in a prospective study.

References

1. [Gilleece M. et al.](#) EBMT ALWP study: myeloablative versus reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia in second complete remission. Oral abstract #OS10-

1. 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Lisbon, PT.

© 2018 Scientific Education Support Ltd. This PDF is provided for personal use only. For wider or commercial use, please seek permission from secretariat@scientificeducationsupport.com and attribute the source as: <http://www.amlglobalportal.com/medical-information/ebmt-2018-mac-versus-ric-allo-hct-in-patients-with-aml-in-cr2>